Idalopirdine as a treatment for Alzheimer’s disease

Bibliography

• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-17
   PubMed Web of Science ®Google Scholar
• Reitz C, Brayne C, Mayeux R. Epidemiology of Alzhiemer disease. Nat Rev Neurol 2011;7(3):137-52
   PubMed Web of Science ®Google Scholar
• Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759-66
   PubMed Web of Science ®Google Scholar
• Galimberti D, Scarpini E. Progress in Alzheimer’s disease. J Neurol 2012;259:201-11
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 2008;25:115-26
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J Neurol Sci 2005;229:43-9
   PubMed Web of Science ®Google Scholar
• Giacobini E, Gold G. Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol 2013;9(12):677-86
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: a historical overview, current perspective, and future directions. Ann N Y Acad Sci 1985;444:332-58
   PubMed Web of Science ®Google Scholar
• Knowles J. Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid 2006;1(3):195-219
   PubMedGoogle Scholar
• Amanatkar HR, Grossberg GT. Transdermal rivastigmine in the treatment of Alzheimer’s disease: current and future directions. Expert Rev Neurother 2014;14(10):1119-25
   PubMed Web of Science ®Google Scholar
• Jiang D, Yang X, Li M, et al. Efficacy and safety of galantamine treatment for patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Neural Transm 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593
   PubMed Web of Science ®Google Scholar
• Kurz A, Grimmer T. Efficacy of memantine hydrochloride once-daily in Alzheimer’s disease. Expert Opin Pharmacother 2014;15(13):1955-60
   PubMed Web of Science ®Google Scholar
• Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320-7
   PubMed Web of Science ®Google Scholar
• Ruat M, Traiffort E, Arrang JM, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localizationand stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993;193:268-76
   PubMed Web of Science ®Google Scholar
• Kohen R, Metcalf MA, Khan N, et al. Cloning, characterization and chromosomal localization of human 5-HT6 serotonin receptor. J Neurochem 1996;66:47-56
   PubMed Web of Science ®Google Scholar
• Yun HM, Rhim H. The serotonin-6 receptor as a novel therapeutic target. Exp Neurobiol 2011;20(4):159-68
   PubMedGoogle Scholar
• Roth BL, Craigo SC, Choudray MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5- hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10
   PubMed Web of Science ®Google Scholar
• Kim HJ, Yun HM, Kim T, et al. Functional human 5-HT6 receptor assay for high throughput screening for chemical ligands and binding proteins. Comb Chem High Throughput Screen 2008;11:316-24
   PubMed Web of Science ®Google Scholar
• Zhang JY, Nawoschik S, Kowal D, et al. Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol 2003;472:33-8
   PubMed Web of Science ®Google Scholar
• Bourson A, Borroni E, Austin RH, et al. Determination of the role of 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 1995;274:173-80
   PubMed Web of Science ®Google Scholar
• Ramirez MJ. 5-HT6 receptors and Alzheimer’s disease. Alzheimers Res Ther 2013;5(2):15
   PubMed Web of Science ®Google Scholar
• Woolley ML, Bentley JC, Sleight AJ, et al. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001;41(2):210-19
   PubMed Web of Science ®Google Scholar
• Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics 2008;5(3):458-69
   PubMed Web of Science ®Google Scholar
• Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010;13(8):1021-33
   PubMed Web of Science ®Google Scholar
• Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol 2008;155(3):434-40
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02122692. NLM Identifier: NCT02122692 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01975779. NLM Identifier: NCT01975779 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02340195. NLM Identifier: NCT02340195 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02231450. NLM Identifier: NCT02231450 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Absolute Bioavailability of Lu AE58054 in Healthy Subjects In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02019394 NLM Identifier: NCT02019394 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Bioequivalence Study of Idalopirdine Tablets 60 mg [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02371707. NLM Identifier: NCT02371707 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer’s Disease [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01019421. NLM Identifier: NCT01019421 [Cited 05 March 2015]
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s Disease. Neurology 1984;34:939-44
   PubMed Web of Science ®Google Scholar
• Available from: http://www.alzforum.org/news/conference-coverage/new-treatments-alzheimers-behavioral-symptoms-horizon
   Google Scholar
• Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2014;13(11):1092-9
   PubMed Web of Science ®Google Scholar
• Schneider LS. Idalopirdine for Alzheimer’s disease: written in the stars. Lancet Neurology 2014;13(11):1063-5
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. Study of Lu AE58054 in Patients With Mild - Moderate Alzheimer’s Disease Treated With Donepezil (STARSHINE) [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01955161. NLM Identifier: NCT01955161 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Lu AE58054 in Patients With Mild-moderate Alzheimer’s Disease Treated With Donepezil (STARBEAM) [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02006641. NLM Identifier: NCT02006641 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Lu AE58054 in Patients With Mild to Moderate Alzheimer’s Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT) [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02006654. NLM Identifier: NCT02006654 [Cited 05 March 2015]
   Google Scholar
• H. Lundbeck A/S. Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer’s Disease (STAR Extension)[Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02079246. NLM Identifier: NCT02079246 [Cited 05 March 2015]
   Google Scholar
• Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB742457, in Alzheimer’s disease. Curr Alzheimer Res 2010;7:374-85
   PubMed Web of Science ®Google Scholar
• Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011;26:536-44
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Study of SB-742457 or Donepezil Versus Placebo in Subjects with Mild-to-moderate Alzheimer’s disease [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00708552x. NLM Identifier: NCT01955161 [Cited 05 March 2015]
   Google Scholar
• Maher-Edwards G, Ascher J, Watson C, et al. 48-week efficacy and tolerability of treatment with SB-742457, a novel 5HT6 receptor antagonist, when added on to donepezil in subjects with mild-to-moderate Alzheimer’s disease (AD). Alzheimer’s Dementia 2011;7(Suppl 4):e5
   Google Scholar
• Schaffhauser H, Mathiasen JR, DiCamillo A, et al. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009;78:1035-42
   PubMed Web of Science ®Google Scholar
• Jones R. Dimebon disappointment. Alzheimers Res Ther 2010;2:25
   PubMed Web of Science ®Google Scholar
• Pfizer. Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer’s Disease With Existing Neuropsychiatric Symptoms On Donepezil[Internet]. Bethesda (MD): National Library of Medicine (US). 2000; Available from: https://www.clinicaltrials.gov/ct2/show/NCT01712074. NLM Identifier: NCT0171207448 [Cited 05 March 2015]
   Google Scholar